Definitive Healthcare Corp. (NASDAQ:DH) Short Interest Update

Definitive Healthcare Corp. (NASDAQ:DH) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 4,830,000 shares, a decline of 35.3% from the February 29th total of 7,470,000 shares. Based on an average trading volume of 572,300 shares, the short-interest ratio is currently 8.4 days. Currently, 10.2% of the shares of the company are short sold.

Definitive Healthcare Price Performance

Shares of DH stock traded up $0.16 during trading hours on Friday, hitting $8.07. 622,191 shares of the company’s stock were exchanged, compared to its average volume of 456,828. The company has a market capitalization of $950.02 million, a PE ratio of -4.53, a PEG ratio of 7.25 and a beta of 1.43. Definitive Healthcare has a 12-month low of $5.53 and a 12-month high of $12.45. The business’s 50 day simple moving average is $8.78 and its 200-day simple moving average is $8.35. The company has a current ratio of 2.31, a quick ratio of 2.31 and a debt-to-equity ratio of 0.20.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.02). The business had revenue of $65.93 million for the quarter, compared to analysts’ expectations of $66.01 million. Definitive Healthcare had a positive return on equity of 0.43% and a negative net margin of 80.40%. On average, equities research analysts anticipate that Definitive Healthcare will post 0.11 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its holdings in Definitive Healthcare by 1,601.9% in the first quarter. Bank of New York Mellon Corp now owns 557,676 shares of the company’s stock valued at $13,746,000 after acquiring an additional 524,908 shares in the last quarter. US Bancorp DE lifted its position in Definitive Healthcare by 81.0% during the first quarter. US Bancorp DE now owns 5,087 shares of the company’s stock valued at $125,000 after buying an additional 2,276 shares during the period. Raymond James Trust N.A. purchased a new position in Definitive Healthcare during the first quarter valued at $296,000. Clearbridge Investments LLC lifted its position in Definitive Healthcare by 17.8% during the first quarter. Clearbridge Investments LLC now owns 2,077,794 shares of the company’s stock valued at $51,218,000 after buying an additional 314,089 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in Definitive Healthcare by 3.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 136,896 shares of the company’s stock valued at $3,375,000 after buying an additional 4,403 shares during the period. Institutional investors own 98.67% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Stifel Nicolaus reduced their price objective on Definitive Healthcare from $12.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday, January 17th. Needham & Company LLC cut shares of Definitive Healthcare from a “buy” rating to a “hold” rating in a report on Wednesday, January 17th. Barclays lifted their price target on shares of Definitive Healthcare from $10.00 to $11.00 and gave the stock an “equal weight” rating in a report on Friday, March 1st. Canaccord Genuity Group boosted their target price on shares of Definitive Healthcare from $9.00 to $10.00 and gave the company a “hold” rating in a report on Thursday, February 29th. Finally, Canaccord Genuity Group lowered Definitive Healthcare from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. Seven research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $11.31.

Definitive Healthcare Company Profile

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.